RadNet, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US7504911022
USD
81.08
2.28 (2.89%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

256.59 k

Shareholding (Mar 2025)

FII

8.17%

Held by 127 FIIs

DII

45.71%

Held by 56 DIIs

Promoter

0.01%

How big is RadNet, Inc.?

22-Jun-2025

As of Jun 18, RadNet, Inc. has a market capitalization of $4.24 billion, with net sales of $1.87 billion and a net profit of $3.69 million over the last four quarters. Shareholder's funds are $902.31 million, and total assets amount to $3.50 billion.

As of Jun 18, RadNet, Inc. has a market capitalization of 4,243.70 million, classifying it as a Small Cap company.<BR><BR>As of Jun 18, the sum of Net Sales for the latest four quarters is 1,869.35 million, while the sum of Net Profit for the same period is 3.69 million.<BR><BR>As of Dec 24, the reporting period shows Shareholder's Funds at 902.31 million and Total Assets at 3,497.16 million.

Read More

What does RadNet, Inc. do?

22-Jun-2025

RadNet, Inc. is a small-cap provider of outpatient diagnostic imaging services, with recent net sales of $471 million and a net profit of -$30 million. The company has a market cap of approximately $4.24 billion and key metrics include a P/E ratio of 137.00 and a debt-to-equity ratio of 0.39.

Overview: <BR>RadNet, Inc. is a provider of freestanding, fixed-site outpatient diagnostic imaging services in the Pharmaceuticals & Biotechnology industry, classified as a small-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 471 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -30 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 4,243.70 Million (Small Cap)<BR><BR>Key Metrics: <BR>P/E: 137.00 <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.39 <BR>Return on Equity: 3.57% <BR>Price to Book: 4.72<BR><BR>Contact Details: <BR>Address: 1510 Cotner Ave, LOS ANGELES CA: 90025-3303 <BR>Tel: 1 310 4787808 <BR>Website: https://www.radnet.com/

Read More

Should I buy, sell or hold RadNet, Inc.?

22-Jun-2025

Who are in the management team of RadNet, Inc.?

22-Jun-2025

As of March 2022, RadNet, Inc.'s management team includes Dr. Howard Berger (Chairman, CEO), Ms. Ruth Wilson (SVP of Human Resources), Dr. John Crues (VP, Medical Director), and several independent directors, including Mr. David Swartz, Mr. Marvin Cadwell, Mr. Lawrence Levitt, and Dr. Michael Sherman. This team is responsible for the company's strategic direction and operations.

As of March 2022, the management team of RadNet, Inc. includes the following individuals:<BR><BR>- Dr. Howard Berger: Chairman of the Board, President, Chief Executive Officer, and Director<BR>- Ms. Ruth Wilson: Senior Vice President of Human Resources and Director<BR>- Dr. John Crues: Vice President, Medical Director, Director, and Corporate Secretary<BR>- Mr. David Swartz: Lead Independent Director<BR>- Mr. Marvin Cadwell: Independent Director<BR>- Mr. Lawrence Levitt: Independent Director<BR>- Dr. Michael Sherman: Independent Director<BR><BR>This team oversees the strategic direction and operations of the company.

Read More

Is RadNet, Inc. overvalued or undervalued?

20-Sep-2025

As of May 12, 2025, RadNet, Inc. is considered overvalued and risky due to high valuation ratios, including a P/E of 137, compared to lower ratios of peers, despite its strong historical performance.

As of 12 May 2025, the valuation grade for RadNet, Inc. has moved from fair to risky, indicating a shift towards a less favorable outlook. The company appears to be overvalued based on its high valuation ratios, including a P/E ratio of 137, an EV to EBITDA of 21.25, and a Price to Book Value of 4.90. In comparison, peers such as Encompass Health Corp. have a significantly lower P/E ratio of 20.94, while The Ensign Group, Inc. shows a P/E of 32.46, both suggesting that RadNet's valuation is not justified relative to its industry.<BR><BR>Despite RadNet's strong historical performance, with a staggering 3-year return of 282.14% compared to the S&P 500's 70.41%, the current valuation metrics indicate that the stock may be priced too high given its earnings potential. Overall, RadNet, Inc. is assessed as overvalued in the current market context.

Read More

Is RadNet, Inc. technically bullish or bearish?

29-Sep-2025

As of September 26, 2025, RadNet, Inc. shows a bullish technical trend supported by daily moving averages and weekly MACD, despite mixed signals from other indicators and underperformance compared to the S&P 500 year-to-date.

As of 26 September 2025, the technical trend for RadNet, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, while the monthly MACD is mildly bearish, indicating mixed signals across time frames. The weekly RSI is bearish, but the monthly RSI shows no signal. Moving averages are bullish on the daily chart, supporting the overall bullish stance. Additionally, Bollinger Bands are mildly bullish weekly and bullish monthly, while the KST and OBV indicators are bullish weekly and mildly bullish monthly. <BR><BR>In terms of performance, RadNet has returned 7.57% over the past month compared to the S&P 500's 2.75%, but it has underperformed year-to-date and over the last year against the benchmark. Overall, the current technical stance is bullish, with strength indicated by the daily moving averages and the weekly MACD.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

High Debt Company with a Debt to Equity ratio (avg) at times

  • Poor long term growth as Operating profit has grown by an annual rate 53.28% of over the last 5 years
  • High Debt Company with a Debt to Equity ratio (avg) at times
  • The company has been able to generate a Return on Equity (avg) of 6.12% signifying low profitability per unit of shareholders funds
2

Poor long term growth as Operating profit has grown by an annual rate 53.28% of over the last 5 years

 
3

The company declared very negative results in Mar'25 after flat results in Dec'24

4

Risky -

5

High Institutional Holdings at 100%

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 5,537 Million (Small Cap)

stock-summary
P/E

137.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.35

stock-summary
Return on Equity

4.80%

stock-summary
Price to Book

5.94

Revenue and Profits:
Net Sales:
498 Million
(Quarterly Results - Jun 2025)
Net Profit:
23 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
14.28%
0%
14.28%
6 Months
38.13%
0%
38.13%
1 Year
0.55%
0%
0.55%
2 Years
134.74%
0%
134.74%
3 Years
300.99%
0%
300.99%
4 Years
200.19%
0%
200.19%
5 Years
328.31%
0%
328.31%

RadNet, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
12.35%
EBIT Growth (5y)
53.28%
EBIT to Interest (avg)
1.26
Debt to EBITDA (avg)
2.58
Net Debt to Equity (avg)
0.39
Sales to Capital Employed (avg)
0.98
Tax Ratio
54.91%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
6.37%
ROE (avg)
6.12%
Valuation key factors
Factor
Value
P/E Ratio
137
Industry P/E
Price to Book Value
4.90
EV to EBIT
57.50
EV to EBITDA
21.25
EV to Capital Employed
3.80
EV to Sales
2.54
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
6.62%
ROE (Latest)
3.57%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bullish
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 90 Schemes (46.04%)

Foreign Institutions

Held by 127 Foreign Institutions (8.17%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 5.69% vs -1.19% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 177.44% vs -309.15% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "498.20",
          "val2": "471.40",
          "chgp": "5.69%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "71.40",
          "val2": "18.60",
          "chgp": "283.87%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "18.20",
          "val2": "18.30",
          "chgp": "-0.55%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-4.80",
          "val2": "-8.90",
          "chgp": "46.07%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "23.00",
          "val2": "-29.70",
          "chgp": "177.44%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "71.20%",
          "val2": "-35.80%",
          "chgp": "10.70%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 13.18% vs 13.04% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 28.05% vs -9.82% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,829.70",
          "val2": "1,616.60",
          "chgp": "13.18%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "249.10",
          "val2": "282.50",
          "chgp": "-11.82%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "93.00",
          "val2": "64.50",
          "chgp": "44.19%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-24.90",
          "val2": "-17.10",
          "chgp": "-45.61%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "38.80",
          "val2": "30.30",
          "chgp": "28.05%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "60.80%",
          "val2": "57.50%",
          "chgp": "0.33%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
498.20
471.40
5.69%
Operating Profit (PBDIT) excl Other Income
71.40
18.60
283.87%
Interest
18.20
18.30
-0.55%
Exceptional Items
-4.80
-8.90
46.07%
Consolidate Net Profit
23.00
-29.70
177.44%
Operating Profit Margin (Excl OI)
71.20%
-35.80%
10.70%
USD in Million.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is 5.69% vs -1.19% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 177.44% vs -309.15% in Mar 2025

Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
1,829.70
1,616.60
13.18%
Operating Profit (PBDIT) excl Other Income
249.10
282.50
-11.82%
Interest
93.00
64.50
44.19%
Exceptional Items
-24.90
-17.10
-45.61%
Consolidate Net Profit
38.80
30.30
28.05%
Operating Profit Margin (Excl OI)
60.80%
57.50%
0.33%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 13.18% vs 13.04% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 28.05% vs -9.82% in Dec 2023

stock-summaryCompany CV
About RadNet, Inc. stock-summary
stock-summary
RadNet, Inc.
Pharmaceuticals & Biotechnology
RadNet, Inc. is a provider of freestanding, fixed-site outpatient diagnostic imaging services in the United States. As of December 31, 2016, the Company operated directly or indirectly through joint ventures, 305 centers located in California, Delaware, Florida, Maryland, New Jersey, New York and Rhode Island. Its centers provide physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Its services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy and other related procedures. As of December 31, 2016, the Company had in operation 257 MRI systems, 157 CT systems, 47 PET or combination PET/CT systems, 48 nuclear medicine systems, 479 X-ray systems, 279 mammography systems, 551 ultrasound systems and 104 fluoroscopy systems.
Company Coordinates stock-summary
Company Details
1510 Cotner Ave , LOS ANGELES CA : 90025-3303
stock-summary
Tel: 1 310 4787808
stock-summary
Registrar Details